Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Thalidomide approved for multiple myeloma and ENL in Australia

Nov. 19, 2003

Swiss prenotification of intent to approve Erbitux

Nov. 18, 2003

Dendreon grants Kirin HLA-DR antibody license, regains Asian Provenge rights

Nov. 18, 2003

ECOG phase III trial of Rituxan reaches primary efficacy endpoint early

Nov. 17, 2003

Two additional pivotal trials for IGN-101

Nov. 14, 2003

Immunomedics negotiating return of epratuzumab rights from Amgen

Nov. 13, 2003

Maxim seeks European approval for Ceplene treatment

Nov. 11, 2003

Final results for phase II study of R-1549 in gastric cancer

Nov. 10, 2003

Actimid enters phase II trial for prostate cancer

Nov. 3, 2003

Anti-EGFR antibody with ADCC-inducing activity

Oct. 31, 2003

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...